Newsletter sign up

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.

ADC University Our services

ADC Review
is made possible by:


Americas Antibody Congress 2017


This May, researchers from pharma, academia, and biotech will descend on San Diego for two days of networking and content on the challenges to the antibody industry presented by the increased demand for antibody drugs to fight chronic illnesses.

With demand comes innovation. The only antibody event with new data and non-repetitive talks as a requirement to speak, Americas Antibody Congress 2017 will feature sessions on New Data in Antibody Discovery, New Data in Clinical and Commercial Development, and the therapeutic areas of Infectious Diseases and Oncology.

Download the brochure

Click here tot register


World Immunotherapy Congress USA 2017

Discover. Develop. Get to market. For Biotech, Pharma, and Their Partners.

The demand for innovation in immunotherapy can only grow, and new breakthroughs are needed if success rates are to continue. That’s why World Immunotherapy Congress is coming to the USA after an acclaimed launch in Europe. This inaugural event will bring together the brightest and best minds in pharma, biotech, government and academia to build on the development and commercialization of new immunotherapy treatments.

Co-located with the Americas Antibody Congress, Immunotherapy World Congress USA features 2 days of in-depth case studies and discussions around Cell Therapy Strategies, Pre-Clinical Development and Innovative Therapeutic Approaches presented by our partners from biopharma and academia.

Click here to register.


CPhI | Pre-Connect Congress 2017

CPhI’s Pre-Connect Congress is the ‘Pharma Leaders’ Destination’ – a one day Congress taking place the day before the CPhI Worldwide Exhibition and covering the latest trends and developments in Pharma across a variety of sectors.

The Pre-Connect Congress is the only event to cover the full spectrum of the Pharma value chain.

Join us in Frankfurt on 23rd October for a series of thought provoking presentations, interactive panel discussions and dedicated networking opportunities, helping you to do better business in Pharma.

7th Annual World ADC Berlin 2017

The last 12 months has seen a staggering amount of progress in ADCs.

There are now 50+ compounds in the clinic; with approval of Pfizer’s Inotuzumab Ozogamicin expected later this year. Coupled with this, there is a bulging preclinical pipeline of 92 ADCs and counting.

In 2017, 300+ of the leading ADC minds will descend on the 7th Annual World ADC Berlin meeting (20-22 February) to share experiences, data and insights on how to develop the next generation of clinically impactful ADCs. Across three streams, every element of ADC development is addressed providing you with an unrivalled forum for learning.

The 2017 World ADC Berlin program has been designed to reflect these progressive innovations developing next-generation ADCs.

The meeting will be held in the Maritim proArte Hotel Berlin,  Friedrichstraße 151,  Berlin,  10117, Germany

SMi’s 6th Annual Conference: Antibodies & Antibody-drug Conjugates

SMi is proud to present their 6th Annual Antibodies and Antibody-drug Conjugates Conference, being held at the Copthorne Tara Hotel, London, UK on the 9th – 10th April 2018.

With an every-growing industry, the market is expected to reach USD 30 Billion by 2023.

Read on to gain your exclusive discount code to attend SMi’s 6th Annual Conference: Antibodies & Antibody-drug Conjugates

Antibodies and antibody-drug conjugates or ADCs have the potential to make a ground-breaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.

Join us this April 2018, as SMi’s ADC Summit conference brings together industry experts from leading life science and pharmaceutical companies. Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.

How Will You Benefit?

  • Network and learn from leading professionals such as or chairs and key speakers
  • Chairs for 2018:
    • Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma
    • Rakesh Dixit, Vice President and Global Head Biologics Safety Assessment, Medimmune
  • Key Speakers Include:
    • Robert Lyon, Senior Director, Seattle Genetics
    • Arnaud Tiberghien, Scientist II, Spirogen
    • Alison Betts, Associate Research Fellow, Pfizer
    • Thomas Pillow, Senior Scientist, Genentech
    • Andreas Pahl, CSO, Heidelberg Pharma
    • Carlo Boutton, Director of Technology, Ablynx
  • Some Featured Highlights will include:
    • Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.
    • Discover new and novel payloads, expanding the ADC landscape:
      • Antibody Targeted Amanitin Conjugates (ATACs) and
      • Minorgroove binding DNA-interactive molecules
    • Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.
    • Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumors.
    • Design principles for maximizing the drug delivery efficiency and therapeutic index.

Click here to view the full agenda.

Discount Code

Exclusive discount code for the readers of ADC Review | Journal of Antibody-drug Conjugates: UK £100 off using code:



CAR-T Congress, Boston, USA | March 20 – 22, 2018

CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematologic malignancies…is CAR-T therapy what we’ve been waiting for?
Join 18+ thought-leaders from biotech, big pharma, academia and the wider service community on 20th – 22nd March 2018 to address the challenges and opportunities of CAR-T therapies.

  • Hear first-hand results from unpublished human and clinical studies
  • Explore the challenges of the tumour microenvironment
  • Understand new approaches to scalability & streamlined cell therapy
  • Discover the next generation of immunotherapy and alternate cell constructs
  • Take advantage of the Commercialization Day and network and share knowledge to understand the commercial opportunities of CAR-T

Hear from top speakers including Ziopharm, Juno Therapeutics, Moffitt Cancer Center, Perelman School of Medicine, University of Pennsylvania and more. Join the conversation and learn more about the future of cell therapy.

To find out more, Click here.


Antibody–Drug Conjugates: Oncology and Beyond

Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.

Organizers  Speakers
Gene Dubowchik, Ph.D,
Bristol-Myers Squibb
Philip E. Brandish, Ph.D,
Merck & Co.
Lynn M. Abell, Ph.D,
Bristol-Myers Squibb
Ryan Fleming, Ph.D,
Pamela A. Trail, Ph.D,
Regeneron Pharmaceuticals Inc.
Rakesh K. Jain, Ph.D,
Harvard University
Sonya Dougal, Ph.D,
The New York Academy of Sciences
Christopher J. O’Donnell, Ph.D,
Caitlin McOmish, Ph.D,
The New York Academy of Sciences
Laura Saunders, Ph.D,
Greg Thurber, Ph.D
University of Michigan

Note: Poster Abstract Deadline is September 15, 2017

Photo: New York city skyline. Courtesy: © 2017 Fotolia. Used with permission.

2nd Annual Cancer Immunotherapy Summit

Vonlanthen Group of Companies, a fast-growing multinational company that is an experienced provider of conferences, summits, exhibitions, and training programs, producing events within 6 different industries,will be hosting the 2nd Annual Cancer Immunotherapy Summit on September 21st – 22nd, 2017 in Vienna, Austria.

Following the success of the 1st Annual Cancer Immunotherapy Summit and the continued viability of immunotherapy as a cancer treatment we bring the second instalment in the series.

Immunotherapy upholds as being one of the most successful approaches to cancer treatment since the discovery of chemotherapy. To pursue this option as a feasible form of treatment, there needs to be an adequate forum for experts to share their findings and technologies. The purpose of this Summit is to bring experts, scientists, and researchers together to discuss the latest research, advancements, and developments in immunotherapy to continue the successful development of this as a form of cancer treatment.

Dr. Saso Cemerski, Principal Scientist, Merck Sharp & Dohme Ltd, USA and chairman of the event, states the importance of this topic and the need for this event: ‘Cancer treatment has moved into a new era with therapies that target the immune system showing unprecedented success in previously difficult to treat indications. While targeting negative T-cell regulators, PD-1 and CTLA-4, drove much of the initial success it also created an immediate need to identify new targets on T-cells and other immune cells present in the tumour microenvironment. Next generation targets, next generation combinations, new technologies and platforms are all critical factors that will allow improvement of the initial clinical success immuno-oncology as a field has brought to patients.

As we continue to work bringing forward from discovery into clinical development drugs that demonstrate strong preclinical proof of concept, we also continue to learn through reverse translation how to best define patient population that will respond to new therapies, how to design best biomarker plans and ultimately, design the best protocols for clinical trials. The 2nd Annual Cancer Immunotherapy Summit will surely be a great opportunity to share some of the latest research and development in the field and stimulate additional progress in the future.’

We are assembling innovators from oncology, drug development, antibody engineering, cell and gene therapy, and others for a two-day summit to espouse the latest developments in Cancer Immunotherapy research. Through a detailed outlay of the current state and future progressions in this form of treatment, attendees will be exposed to new findings. This will include:

  • The success of antibodies in therapeutics and engineering
  • The potential of the next generation immune checkpoint pathways
  • Revolutionary cancer treatments with personalized cancer vaccines
  • Reinforcing anti-tumour immunity
  • Managing unique immune-mediated adverse reactions and toxicity effects in treatment therapies
  • Progressions in genetic engineering techniques and progressions in preclinical and clinical Cancer Immunotherapy
  • Car T-cell therapy as an influence on cancer treatment
  • Regulatory aspects of the EU and the rest of the world for immunotherapy

We are excited to be hosting this critical event, as the outcome will have a lasting impact on cancer treatment therapies. Join us for what will be an engaging and insightful opportunity for those concerned with Cancer Immunotherapy development. Registration is available till September 19, 2017.


8th World ADC – San Diego

Now in it’s 8th year, World ADC in San Diego , CA, shares novel science with transformative research to power the development of more therapeutically effective Antibody-drug Conjugates (ADCs).

This multi-stream, 4 day event covers every element of ADCs from early discovery to marketization. Distilling new insights and data with lessons learned, attendees will be able to craft their own ADC conference focused on your specific challenges.

As the industry’s definitive conference, this antibody drug conjugate conference provides you with an unrivaled forum for learning to propel your ADC program forward tomorrow.

Organized by Hanson Wade, the 8th World ADC in San Diego will be held at Sheraton San Diego Marina, 1380 Harbor Island Dr, San Diego, CA 92101, United States.

Special Discount
Plan to Attend the 8th Annual World ADC Summit in September! As a subscriber get 10% discount when you quote promotional code ADCR10.


Antibody Drug Conjugates Summit

The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness
  • Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
  • Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:

  • Toxicology
  • Biologics
  • Molecular Biology
  • Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
  • Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
  • Oncology Drug Development; Oncology Molecules
  • Medical information
  • Bioanalytical
  • Discovery Chemistry; Research & Development; Antibody Discovery
  • Protein Engineering; Process Sciences
  • Biopharmaceutical Development; Development Analytics and New Technologies:
  • Clinical Assay; Biologics Discovery and Design

It is also designed for professionals who work for the Industry of:

  • Pharmaceuticals,
  • Biologics,
  • Medicine;
  • Clinical Research Organizations;
  • Academic Research Centers;
  • Regulatory Agencies


Skip to toolbar